The new thiosemicarbazones (3a-d) of 3-acetylumbelliferone and Schiff’s bases (4a-b) of 3-acetylcoumarin were synthesized, characterized by elemental analysis, UV–Vis, FT-IR, NMR, and ESI-HR MS, and evaluated for their anticancer potency against the human breast cancer (MCF-7) cell line. All the tested compounds exhibited good to moderate anticancer efficacy in a dose-dependent manner. The synthesized compounds exhibited potent preferential inhibition effects against the MCF-7 cell line, with IC50 range of 147.8–505.1 µg/mL. The most potent compound, (E)-N-(1-(7-hydroxy-2-oxo-2H-chromen-3-yl) ethylidine)-2,6-dimethylmorpholine-4-carbothiohydrazide (3c), showed significant cytotoxicity with an IC50 value of 147.8 µg/mL against the tested cell line. It showed a higher proportion of cells in G1 (37.21 %) and S (26.86 %) phases and a lower proportion of cells in G2 phase (26.37 %), with respect to control. Molecular docking of all the synthesized compounds with target proteins VEGFR2 and EGFR demonstrated their significant binding affinity and interactions with key residues compared to the reference drug (erlotinib). DFT-based analysis showed that all the compounds have effective reactivity due to the low band gap energy of HOMO and LUMO relative to the reference drug, erlotinib (4.26 eV). The reactivity-related quantum mechanical parameters η, S, χ, μ, and ω indicated that these compounds have a high efficacy towards the target enzymes VEGFR2 and EGFR. All of the synthesized compounds had drug-like action, according to ADMET predictions.